BioRestorative Therapies (BRTX) Accumulated Expenses (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Accumulated Expenses came in at $713500.0 in Q4 2025, up 1.35% YoY from $704000.0 in Q4 2024, and up 32.41% on a QoQ basis from $538875.0 in Q3 2025.
BioRestorative Therapies (BRTX) Accumulated Expenses (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Accumulated Expenses data on file, last reported at $713500.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 1.35% year-over-year to $713500.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $713500.0 (up 1.35% YoY) and the FY2025 annual result came in at $713500.0, up 1.35% from the prior year.
- Accumulated Expenses improved to $713500.0 in Q4 2025, from $538875.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $713500.0 in Q4 2025 to a low of $114647.0 in Q3 2022.
- A 5-year average of $422596.0 and a median of $416973.5 in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2021 — Accumulated Expenses surged 10434.26% — and 2022, when it slumped 83.92%.
- Tracing BRTX's Accumulated Expenses over 5 years: stood at $134970.0 in 2021, then retreated by 3.63% to $130072.0 in 2022, then soared by 447.15% to $711686.0 in 2023, then retreated by 1.08% to $704000.0 in 2024, then gained by 1.35% to $713500.0 in 2025.
- The last three Accumulated Expenses figures came in at $713500.0 (Q4 2025), $538875.0 (Q3 2025), and $359250.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 713,500.00 |
| Sep 30, 2025 | 538,875.00 |
| Jun 30, 2025 | 359,250.00 |
| Mar 31, 2025 | 179,625.00 |
| Dec 31, 2024 | 704,000.00 |
| Sep 30, 2024 | 682,237.00 |
| Jun 30, 2024 | 447,622.00 |
| Mar 31, 2024 | 338,343.00 |
| Dec 31, 2023 | 711,686.00 |
| Sep 30, 2023 | 548,954.00 |
| Jun 30, 2023 | 386,325.00 |
| Mar 31, 2023 | 232,984.00 |
| Dec 31, 2022 | 130,072.00 |
| Sep 30, 2022 | 114,647.00 |
| Jun 30, 2022 | 114,659.00 |
| Mar 31, 2022 | 156,037.00 |
| Dec 31, 2021 | 134,970.00 |
| Sep 30, 2021 | 532,005.00 |
| Jun 30, 2021 | 713,064.00 |
| Mar 31, 2021 | 713,064.00 |